Castle Biosciences says JAAD study validates integrated DecisionDx-SCC test in high-risk skin cancer cohort of 572 patients
CSTL•JAAD study validates integrated DecisionDx-SCC
Castle Biosciences highlighted a JAAD-published multicenter validation study of its integrated DecisionDx-SCC test for high-risk cutaneous SCC.
The study found the updated test improved risk stratification versus standard staging, supporting clearer treatment intensity and follow-up decisions.
Risk groups and potential treatment implications
Findings indicated the lowest-risk result could support de-escalation, while the highest-risk result flagged patients more likely to benefit from adjuvant radiation.
The validation covered 572 patients, positioning the refined algorithm as a potential driver of adoption in high-risk SCC management workflows.
